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HAC Human artificial chromosome
MAC Mammalian artificial chromosome




YAC Yeast artificial chromosome
BAC Bacterial artificial chromosome
TAR Transformation-associated recombination
hESc Human embryonic stem cells
MMCT Microcell-mediated chromosome transfer
DMD Duchenne muscular dystrophy
DSBs Double-strand breaks
CENP-A Centromeric modified histone H3
(CENH3, Cid, Cnp1, Cse4, HCP3)
This special issue of Chromosome Research contains 12
invited topical review articles, which cover some of the
most active areas of genome engineering using artificial
chromosomes and engineered nucleases, zinc-finger
nucleases (ZFNs), transcription activator-like effector
nucleases (TALENs), and CRISPR/Cas9. This new field
continues to be rapidly developed and, indeed, in the
past year alone, there have been 513 papers cited in
PubMed that are focused on genome/chromosome
engineering in different organisms ranging from bacte-
ria to plants and animals, as well as in cultured cells such
as ES and iPS cells. These review articles were written
by experts of their respective fields to bring together a
vast amount of literature in a clear and didactic manner.
Four among 12 reviews are focused on the construc-
tion and applications of human and mouse artificial
chromosomes (HACs orMACs). Since their description
in late nineties, ACs carrying a functional kinetochore
were considered a promising system for gene delivery
and expression with the potential to overcome many
problems inherent to viral-based gene transfer systems.
Indeed, ACs avoid the limited cloning capacity, the lack
of copy number control, and the insertional mutagenesis
due to integration into host chromosomes that plague
viral vectors. ACs can be engineered by Btop-down^ and
Bbottom-up^ (or by de novo formation by centromere
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seeding) approaches. The top-down approach has typi-
cally involved a telomere-associated chromosome frag-
mentation technique in the homologous recombination-
proficient chicken DT40 cell line. This approach can
generate linear minichromosomes or ACs ranging in
size from 0.5 to 10 Mb that retain functional centro-
meres and are mitotically stable in human or mouse
cells. The most advanced top-down HAC in which
almost all pericentromeric regions are removed was
constructed in the Oshimura’s lab by several rounds of
the telomere-directed breakage of human chromosome
21 (Oshimura et al. 2013). The bottom-up approach of
HACs generation includes transfection of human cells
with either natural higher-order repeat (HOR) or syn-
thetic alpha-satellite (alphoid) DNA of 30–200 kb
cloned into a circular BAC vector or into a linear YAC
vector carrying telomeric sequences (Basu and Willard
2006). In all cases, HAC formation (a circular HAC if a
BAC is used or a linear HAC if a YAC is used) was
accompanied by 20–30-fold multimerization of the
input DNA. Over the past 14 years, several groups have
reported the successful generation of de novo construct-
ed HACs from different substrates. The size of those
HACs ranges in size from 1 to 10 Mb, and the HACs
have been shown to be mitotically stable both in human
and rodent cells.
Another type of de novo formed artificial chromo-
somes are the satellite DNA-based artificial chromo-
somes (SATACs) that can be made in cells of different
mammalian and plant species. The in vivo generation of
SATACs is based upon the induction of large-scale
amplification via integration of exogenous DNA into
specific chromosomal regions (Holló et al. 1996). The
short arm of acrocentric chromosomes, which contains
tandemly repeated ribosomal RNA genes (rDNA) and
different non-coding satellite DNA sequences, is an
optimal chromosomal region to induce de novo SATAC
formation. Thus, almost any cultured mammalian cell
line is suitable for the production of SATACs. The
potential to use any mammalian cell line for SATAC
formation is a major advantage of this technology over
other de novo HAC and MAC technologies. Further-
more, SATACs have been purified to near homogeneity
by high-speed flow sorting due to their unique nucleo-
tide composition and later used for microinjection into
the pronuclei of murine embryos to generate transgenic
mice. All three described protocols generate
minichromosomes with functional centromeres that
maintain their nuclear location and properly segregate
duringmitotic andmeiotic cell divisions. Several studies
have demonstrated the use of top-down and de novo
generated HACs andMACs for the delivery and expres-
sion of genes in human and rodent gene-deficient cell
lines, the generation of iPS cells and for animal
transgenesis (Kouprina et al. 2014).
In this issue, Dr. Hiroshi Masumoto and co-authors
present data on molecular mechanism for de novo HAC
formation from natural and synthetic alpha-satellite
DNA arrays. Their data clearly demonstrate the critical
role of CENP-A assembly on input DNA for de novo
kinetochore formation. Using synthetic alpha-satellite
DNA arrays containing tet-O sequences, this group
developed the first HAC vector with a regulated centro-
mere that was suitable for gene transfer studies and that
provided a unique method to study individual human
kinetochore.
In his review, Dr. Robert Katona provides a detailed
description of de novo formed satellite DNA-based
mammalian artificial chromosomes (SATACs) and their
comparison with HACs or MACs generated by other
approaches. The SATACs vectors were adapted for gene
delivery and gene expression in human cells by insertion
of a unique gene acceptor loxP site. The vectors were
then used for both the generation of transgenic animals
with stable germline transmission of SATACs and
tissue-specific expression of a therapeutic gene loaded
into the artificial chromosome. Similar to HACs, SATA
Cs could be used in cell therapy protocols, where the
most attractive host cells are versatile multilineage stem
cells, such as adult derived early progenitor cells and
embryonic stem cells that have pluripotent and self-
renewing properties to address multiple disease targets.
In their review, Dr. Daniela Moralli and Dr. Zoia L.
Monaco describe de novo HAC formation from input
alpha-satellite DNA in human embryonic stem cells
(hESc) which until recently had never been reported
before. Transferring intact DNA molecules essential
for HAC formation intact across the cell membrane
has been a challenge for a number of years. A highly
efficient delivery system based on HSV-1 amplicons
was used to target DNA directly to the ES cell nucleus,
and HACs were stably generated in human embryonic
stem cells (hESc) at high frequency. Normally, HAC
delivery to embryonic cells is performed only via carrier
cells. This demonstration of efficient HAC formation in
hESc may result in a new strategy for the delivery of
therapeutic genes that are regulated by tissue-specific
promoters to human target cells for ex vivo treatment.
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It is worth noting that the delivery of transgene-
loaded HACs to desired recipient cells continues to be
a fundamental challenge that impedes gene function
studies as well as for gene therapy. Efficiency of the
HAC transfer from donor cells where the HAC was
generated into the desired recipient host cells still
remains problematic because of a relatively large size
of the HACs. At present, the preferred method tomove a
HAC from donor to recipient cells is microcell-mediated
chromosome transfer (MMCT), a technique developed
nearly 40 years ago (Fournier and Ruddle 1977). How-
ever, the method is tedious and only a restricted number
of donor cell lines, including hamster CHO and mouse
A9 cells, are suitable for microcell generation. In this
issue, Dr. Mitsuo Oshimura and co-authors described
several modifications that increase the efficiency of
HAC transfer into recipient cells. This review also sum-
marizes the lessons learned from studies on the con-
struction of HACs and MACs and their ability to drive
exogenous gene expression in cultured cells and trans-
genic animals via MMCT.
Several studies have demonstrated the use of top-
down and de novo generated HACs for both the delivery
and expression of genes in human gene-deficient cell
lines and also for animal transgenesis. A total compre-
hensive list of genes loaded into HAC vectors is avail-
able in the recent review by Oshimura and co-authors
(Oshimura et al. 2013). Among them are a single copy,
full-length genes containing all their regulatory element
such as: human GCH1, CFTR, Factor FVIII, beta-
globin, TP53, HPRT, VHL, NBS1, CYP3A, IgH, CSN2,
STAT3, as well as a ~90 kb Yamanaka OSKM cell-
reprogramming module. The best example for the cor-
rection of a gene deficiency inmodel mouse and patient-
derived cells by a top-down generated HAC is the use of
the 21HAC carrying the dystrophin (DYS) gene, muta-
tions in which lead to Duchenne muscular dystrophy
(DMD). This gene is extremely large, 2.4 Mb. The
complete correction of a genetic deficiency was first
shown in a human DMD patient-derived cell line and
in iPS cells derived from DMD model (mdx) mice.
Later, Dr. Francesco Tedesco and co-authors demon-
strated amelioration of the dystrophic phenotype in
the mdx mice using a combination of the DYS-HAC
and mesoangioblasts. The genetically corrected
mesoangioblasts engrafted robustly and gave rise to
many dystrophin-positive muscle fibers and muscle sat-
ellite cells in dystrophic mice, leading to morphological
and functional amelioration of the phenotype that lasted
for up to 8 months after transplantation. The same group
applied a similar strategy to human iPS cells from a
DMD patient that were genetically corrected with the
DYS-HAC, thus enabling mesoangioblast-like cells to
differentiate from the iPSCs harboring the DYS-HAC.
In this issue, Dr. Francesco Tedesco summarizes the key
steps that brought human artificial chromosomes into
preclinical research for Duchenne muscular dystrophy.
Two reviews examine recent innovations in chromo-
some engineering that promise to greatly increase the
efficiency of plant breeding. With the current state of art
in minichromosomes and transformation techniques in
plants, it is possible to envision the production of
engineered minichromosomes that contain a large mul-
tiplicity of genes conferring many different useful traits
such as pest resistances, nutritional improvements, and
yield enhancements. Similar to HACs, plant
minichromosomes can be engineered by top-down and
bottom-up approaches. Notably, the plant bottom-up
approach is based on tethering of cenH3 to a predefined
chromosomal site resulting in the formation of
neocentromere followed by fragmentation of the
dicentric chromosome. As in HACs, the constructed
advanced plant minichromosomes also use site-
specific recombination system (e.g., Cre/loxP) to insert
a cluster of genes of interest. The sequential insertion of
multiple expression modules would also be feasible by
using Cre/loxP in combination with alternative site-
specific recombination systems such as, for example,
phiC31 integrase.
In this issue, Dr. Michael Mette and Dr. Andreas
Houben described recent approaches to manipulate
individual plant chromosomes in a targeted manner in
order to adapt them to needs of green biotechnology. In
this context, they outline the advantages of engineering
minichromosomes as vectors for transgenes in contrast
to conventional transformation methods and discuss the
basic strategies that can be followed to customize chro-
mosomes in plants. In another review, Dr. James A.
Birchler summarizes data on epigenetic control of
kinetochore in plant and describes a general approach
of telomere-mediated chromosomal truncation using Ti
plasmid as well as methods to recover truncation events.
He specifically discusses an advantage of extra B chro-
mosomes for minichromosome construction. B chromo-
somes exist in a variety of plants and animals and
usually are relatively inert. Potential basic and applied
applications of synthetic chromosomes are also
discussed in this review.
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In the past few years, new genome editing tools have
been developed that cut DNA in a precise and program-
mable manner. These new programmable endonucle-
ases include zinc-finger nucleases (ZFNs), transcription
activator-like endonucleases (TALENs), and the most
recent addition is RNA-programmed genome editors
(CRISPR/Cas9). These targetable nucleases are used to
induce double-strand breaks (DSBs) at specific DNA
sites which are then repaired by mechanisms that can be
exploited to create sequence alterations at the cleavage
site. Current results indicate that these tools can be
successfully employed in a broad range of organisms
which empowers them to be useful tools for improving
the understanding of complex physiological systems,
producing transgenic animals, including creating large
animal models for human diseases, creating transgenic
plants, and even for treating human genetic diseases.
Also in this issue are three reviews summarizing the
recent progress in genome targeting. Dr. Marc Beyer
and co-authors highlight the major technological
improvements for genome editing in murine oocytes
which have been achieved using TALENs. They also
discussed current limitations of the technology, sug-
gested strategies to broadly apply TALENs, and
described possible future directions to facilitate gene
editing in murine oocytes.
Dr. Bjoern Petersen and Dr. Heiner Niemann provide
an update on the use of zinc-finger nucleases (ZFNs) to
modify the genome of farm animals, summarize current
knowledge on the underlying mechanism, and discuss
new opportunities for generating genetically modified
farm animals. Transgenic farm animals, specifically the
domestic pig, share many genetic, anatomical, and physi-
ological features with humans and may thus represent a
suitable model for specific diseases, including cystic fibro-
sis, diabetes, cancer, and several neurological disorders.
In his review, Dr. ZhongdeWang provides a compar-
ative analysis of works on genome engineering in cattle
using engineered zinc-finger nucleases (ZFNs), TALEN
proteins, and CRISPR-Cas9 nucleases. Of these three,
CRISPR/Cas9 seems to show the greatest promise and
flexibility for genetic engineering. However, sequence
requirements of the PAM sequence may constrain some
applications of this technology. Moreover, additional
studies are required to evaluate the specificity and tox-
icity of RNA-guided DNA endonucleases in vitro and
in vivo. These studies on new programmable endonu-
cleases could help to improve the design of next-
generation genome editing tools.
It is well known that mosquitoes are high impact
disease vectors that transmit pathogenic agents that
cause diseases such as malaria, yellow fever,
chikungunya, and dengue. Techniques such as the sterile
insect technique and release of insects with dominant
lethality are currently being investigated to control mos-
quito population. In this issue, Dr. Zach N. Adelman and
co-authors update a progress in the use of site-specific
nucleases for chromosome editing in insects. The
authors emphasize that some organisms may differ from
each other in efficiency of known DNA repair path-
ways. Therefore, more research on the peculiarities of
DNA repair pathways in mosquitoes are needed to
achieve more precise chromosomal engineering of this
organism.
In this issue, Dr. Philip D. Weyman and co-authors
from the J. Craig Venter Institute outlined recent prog-
ress in the methodology for acquiring chromosomes and
chromosome-scale DNA molecules in Bacillus subtilis,
Escherichia coli, and Saccharomyces cerevisiae. Clon-
ing and propagating the entire genome of one bacterium
within another was first demonstrated in 2005. Using
yeast S. cerevisiae to clone whole bacterial genomes as
circular yeast artificial chromosomes (YACs) was a
breakthrough for synthetic biology. Yeast recombina-
tional machinery also allows the assembling of multiple
overlapping genomic fragments into entire genome in a
single step by transformation-associated recombination
(TAR) (Kouprina and Larionov 2006). Right now, sev-
eral complete bacterial genomes (with range from 0.6 to
2.7 Mb) have been assembled by TAR into YACs that
are stable propagated in yeast cells. Another advantage
of yeast as a host for microbe genomes is that the cloned
chromosomes or chromosome fragments can be easily
manipulated using powerful yeast genetic tools. It is
worth noting that yeast cells remain a unique system
for selective isolation of any desirable genomic frag-
ment or gene from total genomic DNAs, using TAR
cloning protocol. So far, this is the only approach able to
isolate full-length genes that are tens of kilobase in size
from mammalian genomes for their complementation
analysis using HAC vectors (Kim et al. 2011).
To summarize, the reviews presented here clearly
demonstrate the great progress that has been accom-
plished in the field of genome engineering using artifi-
cial chromosomes and site-specific nucleases that give a
wide spectrum of promises from development of new
transgenic animal models to therapeutic use in cell ther-
apy, gene therapy, and immunotherapy.
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As guest editors, we thank all our colleagues who
contributed such outstanding articles to this issue. It was
such a pleasure to work with them from invitation to
final production. We also acknowledge Conly Rieder
and Beth Sullivan, Editor-in-Chief and Executive Editor
ofChromosome Research, for their guidance during this
endeavor and for establishing the high standards found
in this journal.
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